FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3007983591> ?p ?o ?g. }

• W3007983591 abstract "633 Background: I+N is now standard of care for first line treatment of intermediate/poor risk mRCC patients (pts). Real world data is vital to understand drug usage, toxicity and outcomes in non-trial pts. This project describes the amount and tolerability of treatment delivered including discontinuation rates, reasons for discontinuation and outcomes from the CKCis database. Methods: Pts in CKCis, a prospective Canadian database from 15 academic centers, who received first line I+N were included. The number of doses of I+N, number of pts who received single-agent nivolumab (N) and duration of single agent N were determined. Reasons for treatment discontinuation, including the rate, type, and grade of toxicities were identified. Efficacy outcomes included time to failure (TTF – time to progression, death, or second line therapy), overall response rate (ORR) and overall survival (OS). Results: The cohort consists of 182 pts. Median age was 63 yrs, 71% had clear cell histology, 11% were on a clinical trial, the IMDC risk distribution was 5% good, 63% intermediate, 32% poor. Median follow up was 8.8 m. All 4 I+N doses were received by 30% of pts of which 78% went on to receive single-agent N. Less than 4 doses of I+N were received by 70% of pts of which 28% went on to receive single-agent N. The median time on single agent N was 5.7 m. In the entire cohort, 21% of patients discontinued therapy due to toxicity. The most common toxicity events were colitis (56% of all events), pneumonitis (19%), and hepatitis (8%). There were no toxicity-related deaths. Median OS has not been reached (22 events to date). Median TTF was 12.4 m. ORR was 32% (5% complete responses). 26% of pts received second line treatment, the most common being sunitinib in 79%. Conclusions: In this real world cohort, the majority of mRCC pts did not receive all 4 doses of I+N, contrasting with clinical trial reporting, yet many of these pts went on to receive single agent N. Discontinuation rates due to toxicity were similar to those reported in CheckMate 214. Further follow up is ongoing and efficacy outcomes analyzed on the basis of treatment quantity/duration will be presented." @default.
• W3007983591 created "2020-03-06" @default.
• W3007983591 creator A5007063312 @default.
• W3007983591 creator A5013185325 @default.
• W3007983591 creator A5017887586 @default.
• W3007983591 creator A5022267545 @default.
• W3007983591 creator A5028194267 @default.
• W3007983591 creator A5028436511 @default.
• W3007983591 creator A5033181043 @default.
• W3007983591 creator A5034541004 @default.
• W3007983591 creator A5037646183 @default.
• W3007983591 creator A5054133193 @default.
• W3007983591 creator A5064078958 @default.
• W3007983591 creator A5069016257 @default.
• W3007983591 creator A5071086661 @default.
• W3007983591 creator A5077514210 @default.
• W3007983591 creator A5082859060 @default.
• W3007983591 creator A5087150696 @default.
• W3007983591 date "2020-02-20" @default.
• W3007983591 modified "2023-10-17" @default.
• W3007983591 title "Real-world utilization and safety of ipilimumab plus nivolumab (I+N) in metastatic renal cell carcinoma (mRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis)." @default.
• W3007983591 doi "https://doi.org/10.1200/jco.2020.38.6_suppl.633" @default.
• W3007983591 hasPublicationYear "2020" @default.
• W3007983591 type Work @default.
• W3007983591 sameAs 3007983591 @default.
• W3007983591 citedByCount "0" @default.
• W3007983591 crossrefType "journal-article" @default.
• W3007983591 hasAuthorship W3007983591A5007063312 @default.
• W3007983591 hasAuthorship W3007983591A5013185325 @default.
• W3007983591 hasAuthorship W3007983591A5017887586 @default.
• W3007983591 hasAuthorship W3007983591A5022267545 @default.
• W3007983591 hasAuthorship W3007983591A5028194267 @default.
• W3007983591 hasAuthorship W3007983591A5028436511 @default.
• W3007983591 hasAuthorship W3007983591A5033181043 @default.
• W3007983591 hasAuthorship W3007983591A5034541004 @default.
• W3007983591 hasAuthorship W3007983591A5037646183 @default.
• W3007983591 hasAuthorship W3007983591A5054133193 @default.
• W3007983591 hasAuthorship W3007983591A5064078958 @default.
• W3007983591 hasAuthorship W3007983591A5069016257 @default.
• W3007983591 hasAuthorship W3007983591A5071086661 @default.
• W3007983591 hasAuthorship W3007983591A5077514210 @default.
• W3007983591 hasAuthorship W3007983591A5082859060 @default.
• W3007983591 hasAuthorship W3007983591A5087150696 @default.
• W3007983591 hasConcept C121608353 @default.
• W3007983591 hasConcept C126322002 @default.
• W3007983591 hasConcept C141071460 @default.
• W3007983591 hasConcept C143998085 @default.
• W3007983591 hasConcept C197934379 @default.
• W3007983591 hasConcept C207103383 @default.
• W3007983591 hasConcept C2777472916 @default.
• W3007983591 hasConcept C2777701055 @default.
• W3007983591 hasConcept C2778375690 @default.
• W3007983591 hasConcept C2778715236 @default.
• W3007983591 hasConcept C2780030458 @default.
• W3007983591 hasConcept C2781433595 @default.
• W3007983591 hasConcept C44249647 @default.
• W3007983591 hasConcept C71924100 @default.
• W3007983591 hasConcept C72563966 @default.
• W3007983591 hasConceptScore W3007983591C121608353 @default.
• W3007983591 hasConceptScore W3007983591C126322002 @default.
• W3007983591 hasConceptScore W3007983591C141071460 @default.
• W3007983591 hasConceptScore W3007983591C143998085 @default.
• W3007983591 hasConceptScore W3007983591C197934379 @default.
• W3007983591 hasConceptScore W3007983591C207103383 @default.
• W3007983591 hasConceptScore W3007983591C2777472916 @default.
• W3007983591 hasConceptScore W3007983591C2777701055 @default.
• W3007983591 hasConceptScore W3007983591C2778375690 @default.
• W3007983591 hasConceptScore W3007983591C2778715236 @default.
• W3007983591 hasConceptScore W3007983591C2780030458 @default.
• W3007983591 hasConceptScore W3007983591C2781433595 @default.
• W3007983591 hasConceptScore W3007983591C44249647 @default.
• W3007983591 hasConceptScore W3007983591C71924100 @default.
• W3007983591 hasConceptScore W3007983591C72563966 @default.
• W3007983591 hasLocation W30079835911 @default.
• W3007983591 hasOpenAccess W3007983591 @default.
• W3007983591 hasPrimaryLocation W30079835911 @default.
• W3007983591 hasRelatedWork W10741706 @default.
• W3007983591 hasRelatedWork W14290189 @default.
• W3007983591 hasRelatedWork W17139308 @default.
• W3007983591 hasRelatedWork W20763325 @default.
• W3007983591 hasRelatedWork W3136001 @default.
• W3007983591 hasRelatedWork W5447729 @default.
• W3007983591 hasRelatedWork W6095507 @default.
• W3007983591 hasRelatedWork W6776275 @default.
• W3007983591 hasRelatedWork W14949086 @default.
• W3007983591 hasRelatedWork W7988773 @default.
• W3007983591 isParatext "false" @default.
• W3007983591 isRetracted "false" @default.
• W3007983591 magId "3007983591" @default.
• W3007983591 workType "article" @default.